PharmAust Limited announce an agreement with Pathway Vet Alliance dba as Thrive Pet Healthcare and Heart of Texas (HoT) Veterinary Specialty Centre in the USA to join the MPL pet dog B cell lymphoma trial. PharmAust will send sufficient tablets for HoT to treat up to 10 dogs according to FDA pilot program guidelines. This US expansion builds on PharmAust's new trial site in New Zealand.

The New Zealand site recently completed its first 28 day treatment of a dog with B cell lymphoma for a successful trial outcome. Trial recruitment continues in Australia with PharmAust successfully fulfilling interim Phase 2 trial endpoints. 25 pet dogs have now been treated using MPL monotherapy.

With continued positive outcomes, PharmAust is preparing for a successful Phase 2 completion and the commencement of a subsequent registration trial. In addition to the trial MPL monotherapy, eight dogs have now been treated post-trial using ongoing MPL in combination with standard of care prednisolone. This MPL and prednisolone combination has to date provided median and average survival times of approximately 140 days or 20 weeks.

This compares favourably with the eight to nine week median and average survival times expected for dogs with B cell lymphoma treated with prednisolone alone. Furthermore, high qualities of life for dogs and their owners have been reported on this combination treatment.